Generic Name and Formulations:
Nitroglycerin 2% (15mg/inch); oint; contains lanolin.
- Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia
- Temozolomide with Radiotherapy Safer, Equally Effective as Nitrosureas for Anaplastic Astrocytoma
- Government: Access to Health Marketplace is Improving, Secure
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Primary Cutaneous B-Cell Lymphoma Treatment Regimens
- Common Medical Abbreviations
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Adult T-Cell Leukemia/Lymphoma
Indications for NITRO-BID:
Prophylaxis of angina. Not for acute attacks.
Apply, using applicator, usually to the chest and occlude. Initially ½ inch on awakening and then 6 hrs later; may increase to 1 inch, then to 2 inches twice daily.
Acute MI. CHF. Hypotension. Volume depleted. Hypertrophic cardiomyopathy. Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with sildenafil. Vasodilating effects potentiated with alcohol, other vasodilators. Orthostatic hypotension with calcium channel blockers.
Headache, dizziness, flushing, orthostatic hypotension, rash; syncope, methemoglobinemia (rare).
Oint—30g, 60g (w. applicator); Oint—48 x 1g packets
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline